MEG3 and cancer: It is reported that WT1 mutations are associated with an extremely poor outcome,15 and they can lead to progression of leukemia by conferring drug resistance.16, 17 Dysregulation of the WT1 gene by epigenetic modifications or mutations might promote leukemic cell proliferation and impair differentiation.18, 19 However, the role of WT1 in regulating cancer-related gene expression remains largely unknown, especially whether WT1 controls MEG3 activity has yet to be explored.